본문바로가기
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
새창열기 아이콘
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
sitemap
About Us
SK bioscience
Company Overview
History
Vision
Contact Us
Leadership
Message from the CEO
Headquarters & Facilities
SK bioscience Headquarters
R&D Center
L HOUSE
Subsidiary
SK bioscience USA
IDT Biologika
Science & Technology
Pipeline
R&D
Production
Business
Business Overview
Domestic
Overseas Business
Vaccine Co-Development
and Technology Transfer
CDMO/CMO
Products
In-house Products
Outsourced Products
Global Partnerships
ESG
IR
Corporate Governance
Company Information
Financial Information
Financial Statements
Financial Credit
Audit Reports
Investment Information
Stock Prices
Shareholder Status
IR Documents
Disclosure
PR
Press Releases
Media Zoom
Brochure
CI Guideline
사이트맵 닫기
Language
KOR
ENG
LinkedIn
YouTube
ESG
SK careers
C/S
SK ethics
Q
U
I
C
K
PR
SK bioscience company news updates
PR
About Us
Science & Technology
Business
ESG
IR
PR
Press Releases
Press Releases
Media Zoom
Brochure
CI Guideline
Press Releases
SK bioscience Secures Additional PAHO Contract to Supply Varicella Vaccines to Latin America
2025.02.28
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
2025.02.25
Korea Begins Administration of Its First RSV Preventive Antibody Injection, ´Beyfortus®´
2025.02.14
SK bioscience Collaborates with WHO to Strengthen Infectious Disease Response … Demonstrates Technological Excellence Through SARS International Standard Material Research
2025.02.12
SK bioscience and Sanofi Expand Partnership to Target the Domestic Market for RSV and Hepatitis A Prevention Medicines
2025.01.23
SK bioscience-Sanofi’s 21-Valent Pneumococcal Conjugate Vaccine Candidate for Phase 3 Studies IND Amendment Review Completed by U.S. FDA
2025.01.17
SK bioscience and Sanofi Expand Partnership to Develop Next-Generation Pneumococcal Conjugate Vaccines
2024.12.23
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
2024.12.12
SK bioscience Receives Approval of Quadrivalent Influenza Vaccine in Indonesia
2024.10.23
SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
2024.10.08
SK bioscience Completes Acquisition of IDT Biologika
2024.10.02
SK bioscience and CEPI Deepen Partnership for Pandemic Prevention, Preparedness and Response
2024.08.30
처음
이전
1
2
3
4
5
6
7
8
9
10
다음
끝
